comparemela.com

Latest Breaking News On - Therapeutics clinical research - Page 4 : comparemela.com

Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0 3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

FDA has set a target action date of December 16, 2023NDA supported by positive efficacy and safety data from the Phase 2 and pivotal Phase 3 trials of roflumilast foamIf approved, roflumilast foam. | April 18, 2023

Frank watanabeAmanda sheldonDrug administrationArcutis biotherapeutics incHead of corporate communicationsExchange commissionClinical dermatology at therapeutics researchPrescription drug user fee actNeal bhatiaClinical dermatologyTherapeutics clinical researchArcuti phaseInvestigator global assessmentPrivate securities litigation reform actArcutis biotherapeuticsNc stock exchange

FDA Accepts Review of Drug Application of Roflumilast Foam for Seborrheic Dermatitis

It was announced by Arcutis Biotherapeutics that the US Food and Drug Administration had accepted for review their NDA for roflumilast foam 0.3%.

Arcutis biotherapeuticNeal bhatiaArcutis biotherapeuticsClinical dermatology at therapeutics researchDrug administrationPrescription drug user free actClinical dermatologyTherapeutics clinical researchApplied topicallyInvestigator global assessmentNew drug applicationRoflumilast foamSeborrheic dermatitisIndividuals agedData indicates roflumilast foam helpful

Soligenix Announces Formation of Psoriasis Medical Advisory Board

Phase 2a clinical study in mild-to-moderate psoriasis initiating in December 2022PRINCETON, N.J., Oct. 25, 2022 /PRNewswire/ Soligenix, Inc. (N.

United statesAnn arborSan diegoSanta monicaEmory university school of medicineGeorge hanJonathans weissChristopherj schaberPauls yamauchiHofstra northwellNeal bhatiaUs congressNational institute of allergyDermatology institute skin care centerUniversity of michiganYork state society of dermatology

FDA OKs New Topical for Inflammatory Rosacea

Almost half of patients clear of lesions or nearly so with benzoyl peroxide 5% cream (Epsolay)

San diegoUnited statesNeal bhatiaTherapeutics clinical researchSol gel technologiesInvestigator global assessmentManaging editorMedpage today

Soligenix Corporate Update Letter - Key Highlights and Upcoming Catalysts

Soligenix Corporate Update Letter - Key Highlights and Upcoming Catalysts - read this article along with other careers information, tips and advice on BioSpace

San diegoUnited statesNew jerseyUnited kingdomWhite houseDistrict of columbiaChristopherj schaberPontifax medisonNeal bhatiaAxel lehrerUs congressEmergent manufacturing operations baltimorePublic health solutions business segmentEmergent product development gaithersburgNational institute of allergyEmergent biosolutions inc

vimarsana © 2020. All Rights Reserved.